CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Entresto™ 49Mg-51 mg tabletdrug
Likely dose
Entresto™ 49Mg-51 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03506412
NCT03506412Phase 4Completed
CompareCT.gov

A Proof of Concept Study to Determine the Efficacy of Entresto™ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study

Mayo Clinic·interventional·Posted Apr 24, 2018·Updated Feb 4, 2022

In Brief

A Phase 4 clinical trial evaluating Entresto™ 49Mg-51 mg tablet for Heart Failure With Preserved Ejection Fraction. Completed, enrolled 40 participants across 1 site.

Detailed Summary

To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure With Preserved Ejection Fraction
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 24, 2018
Enrollment StartJun 25, 2018
Primary CompletionMar 23, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.2 years ago

Interventions

Entresto™ 49Mg-51 mg tabletdrug

Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks